Supriya Lifescience share news, announcements and annual reports
NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap
Supriya Lifescience Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2021 · Issue price ₹274
Last close ₹847.30down ₹22.00 (2.53%)BSE ₹846.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹869.30.
30 Oct: open ₹869.30, high ₹880.45, low ₹841.80
52-week range of traded prices to 30 Oct 2026
₹545.50Low, 24 Mar 2026₹1,085.00High, 1 Jun 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,819 Cr733rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 92,05249.3% delivered
Supriya Lifescience share news and announcements
384 announcements, routine notices left out, newest first. Page 2 of 8.
Oct 2025
Sep 2025
11 Sep · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Aug 2025
13 Aug · General Updates
13 Aug · Results
7 Aug · Analysts
6 Aug · Board meeting
Jul 2025
18 Jul · Analysts
17 Jul · Analysts
Jun 2025
26 Jun · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
May 2025
28 May · Business
21 May · Analysts
Apr 2025
15 Apr · Analysts
Mar 2025
24 Mar · Meeting
Feb 2025
26 Feb · Analysts
26 Feb · Analysts
26 Feb · Analysts
25 Feb · Analysts
10 Feb · Analysts
10 Feb · Analysts
Jan 2025
24 Jan · Results